Novo Nordisk’s blockbuster semaglutide franchise – Rybelsus and Ozempic for type 2 diabetes and Wegovy for obesity – was included in the Centers for Medicare and Medicaid Services (CMS) list of 15 dru
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. B+L Bolsters Ophthalmology With Acquis
Norwich Pharmaceuticals has seen denied its petition for the US Supreme Court to review litigation that has blocked its generic version of Bausch Health’s Xifaxan (rifaximin) from being approved by th
Carving out a patent-protected indication could not save Norwich Pharmaceuticals from having its generic blocked from US Food and Drug Administration approval. The US Supreme Court on 18 November deni